An object of a first aspect of the present invention is to provide a radical generating catalyst that can generate (produce) radicals under mild conditions. In order to achieve the above object, a first radical generating catalyst according to the first aspect of the present invention is characterized in that it includes ammonium and/or a salt thereof. A second radical generating catalyst according to the first aspect of the present invention is characterized in that it includes an organic compound having Lewis acidic properties and/or Brønsted acidic properties.

Disclosed herein are methods of treating a subject having, or at risk of developing, acute respiratory distress syndrome (ARDS) by administering a chlorite composition in an amount effective to treat the subject. Aspects of the methods also include administering a chlorite formulation to a subject having or suspected of having a coronavirus infection, e.g., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), severe acute respiratory syndrome (SARS-CoV), or Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Also disclosed herein are methods of regulating macrophage activity in a subject having, or at risk of developing ARDS by contacting a macrophage of a subject having or at risk of developing ARDS with a chlorite composition in an amount effective to regulate one or more functional properties of the macrophage. The disclosure also features methods of determining inhibition of a ARDS-induced macrophage activity by a chlorite agent.

Disclosed herein are methods of treating a subject having, or at risk of developing, acute respiratory distress syndrome (ARDS) by administering a chlorite composition in an amount effective to treat the subject. Aspects of the methods also include administering a chlorite formulation to a subject having or suspected of having a coronavirus infection, e.g., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), severe acute respiratory syndrome (SARS-CoV), or Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Also disclosed herein are methods of regulating macrophage activity in a subject having, or at risk of developing ARDS by contacting a macrophage of a subject having or at risk of developing ARDS with a chlorite composition in an amount effective to regulate one or more functional properties of the macrophage. The disclosure also features methods of determining inhibition of a ARDS-induced macrophage activity by a chlorite agent.

Disclosed are intravenous solution compositions comprising hypochlorous acid (HOCl) suitable for systemic treatment or prevention of a variety of infections.

Disclosed are intravenous solution compositions comprising hypochlorous acid (HOCl) suitable for systemic treatment or prevention of a variety of infections.

A composition for lubricant formulations is disclosed. The composition may include hypochlorite, dimethicone, and an emulsifier for improvement of lubricity. Methods of making and using the lubricant formulations are also disclosed.

A composition for lubricant formulations is disclosed. The composition may include hypochlorite, dimethicone, and an emulsifier for improvement of lubricity. Methods of making and using the lubricant formulations are also disclosed.

Method and composition for treating or preventing a respiratory illness. The method includes administering at least one dose of a pharmaceutically acceptable fluid having a pH less than 3.0 into contact with at least one region of the respiratory tract present in a patient in need thereof. Respiratory illness that can be treated include COVID-19.

Method and composition for treating or preventing a respiratory illness. The method includes administering at least one dose of a pharmaceutically acceptable fluid having a pH less than 3.0 into contact with at least one region of the respiratory tract present in a patient in need thereof. Respiratory illness that can be treated include COVID-19.

Method and composition for treating or preventing a respiratory illness. The method includes administering at least one dose of a pharmaceutically acceptable fluid having a pH less than 3.0 into contact with at least one region of the respiratory tract present in a patient in need thereof. Respiratory illness that can be treated include COVID-19.